Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Modulation of BCL11A for treatment of hemoglobinopathies

Modulation of BCL11A for treatment of hemoglobinopathies

US Patent 10570392 · Granted Feb 25, 2020

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Functional genomics using CRISPR-CAS systems for saturating mutagenesis of non-c2025
Lineage tracing using mitochondrial genome mutations and single cell genomics2024
Functional genomics using CRISPR-Cas systems for saturating mutagenesis of non-c2023
Targeting BCL11A enhancer functional regions for fetal hemoglobin reinduction2023
Targeting BCL11A distal regulatory elements for fetal hemoglobin reinduction2023
Nuclease-mediated regulation of gene expression2021
Targeting BCL11A distal regulatory elements for fetal hemoglobin reinduction2019
Stablized EZH2 peptides2019
Modulation of BCL11A for treatment of hemoglobinopathies2019
Modulation of BCL11A for treatment of hemoglobinopathies2019
Modulation of BCL11A for treatment of hemoglobinopathies2018
Modulation of BCL11A for treatment of hemoglobinopathies2018